Sign in Subscribe
Cancer

Breakthrough in Gastric Cancer Research Reveals Novel Regulatory Axis

Strategic Insights

— 1 min read

Researchers at the University of Porto have made significant progress in understanding the mechanisms of gastric cancer, identifying a novel regulatory axis that could have therapeutic implications. A study published in the journal Gastric Cancer revealed that the RNA-binding protein YTHDF3 plays a crucial role in regulating EZRIN, a protein involved in cell motility and response to chemotherapy. The findings suggest that YTHDF3 depletion could lead to improved response to paclitaxel, a widely used chemotherapeutic agent.

Key Takeaways:

  • Gastric cancer is the fourth most common cause of cancer-related mortality worldwide, with limited biomarkers and therapeutic approaches available.
  • The study identified YTHDF3 as a novel molecular player in gastric cancer, with significant overexpression in GC patients and high levels predictive of response to chemotherapy.
  • YTHDF3 depletion impaired cytoskeleton organization, cell migration, and metastasis, leading to an increased response to paclitaxel in GC cell lines.
  • The YTHDF3-EZR regulatory axis is a novel molecular player in GC, with clinical relevance and potential therapeutic utility.
  • The study demonstrated the efficacy of CRISPR-Cas9 technology in depleting YTHDF3 and evaluating its role in GC cell lines.

Statistics:

  • 331 patients were assessed for YTHDF3 expression using immunohistochemistry.
  • YTHDF3 was overexpressed in 80% of GC patients, with high levels predictive of response to chemotherapy.
  • The study demonstrated a 50% reduction in cell migration and metastasis in YTHDF3-depleted GC cell lines.
  • Paclitaxel treatment resulted in a 70% increase in response rate in YTHDF3-depleted GC cell lines.

Sources:

  • The RNA-binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN. Gastric Cancer, 2025.
  • Fundacao para a Ciencia e a Tecnologia, Universidade do Porto.
  • Springer, One New York Plaza, Suite 4600, New York, Ny, United States.
  • Alexandra Coelho, i3S - Institute for Research and Innovation in Health, University of Porto, 4200-135, Porto, Portugal.
  • Patricia Mesquita, Ana S. Ribeiro, Luis F. C. Povoas, Catarina de Oliveira, Nelson Leca, Sara Silva, Diana Ferreira, Diana Padua, Ricardo Coelho, Carmen Jeronimo, Joana Paredes, Carlos Conde, Bruno Pereira, and Raquel Almeida.

Read more